VolitionRX Ltd
Open
2.38 -1.24
Overview
Share price change
24h
Min
2.3
Max
2.56
Income | -401K -6.7M |
|---|---|
Sales | 538K 985K |
EPS | -0.051 |
Profit margin | -680.512 |
Employees | 75 |
EBITDA | -143K -5.1M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +864.91% upside |
Next Earnings | 13 Aug 2026 |
|---|
Market Cap | 1.9M 18M |
|---|---|
Previous open | 3.62 |
Previous close | 2.38 |
VolitionRX Ltd Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
VolitionRX Ltd Forecast
Price Target
By TipRanks
864.91% upside
12 Months Forecast
Average 22 USD 864.91%
High 24 USD
Low 20 USD
Based on 3 Wall Street analysts offering 12 month price targets forVolitionRX Ltd - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About VolitionRX Ltd
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.
